Using botulinum toxin for pelvic indications in women

Archana Rao, Jason Abbott
The Australian & New Zealand journal of obstetrics & gynaecology · 2009 · vol. 49(4) , pp. 352–357 · doi:10.1111/j.1479-828x.2009.01028.x · PMID:19694687 · W2082015445
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-15 ⓘ

This review examines botulinum toxin's use and efficacy for gynecological conditions like chronic pelvic pain and detrusor overactivity, noting improvements in some pain symptoms but limited class I evidence for others.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Botulinum toxin (BoNT) is a potent neurotoxin. Its ability to cause muscle paralysis is increasingly being utilised for the management of a number of conditions of interest to the gynaecologist. AIMS: This review aims to give the reader an overview of the use of BoNT for conditions presenting a management challenge for the gynaecologist, such as chronic pelvic pain and idiopathic detrusor overactivity. METHODS: The literature was reviewed regarding the use, side-effects and complications of BoNT in the pelvis, focussing on chronic pelvic pain, provoked vestibulodynia, conditions involving the lower gastrointestinal tract and detrusor overactivity. RESULTS: In terms of pain caused by pelvic floor spasm, daily pelvic pain and dyspareunia are the symptoms most likely to be improved by BoNT. Limited data regarding use for provoked vestibulodynia indicate an improvement in pain scores. In the lower gastrointestinal tract, injection into puborectalis has been showed to objectively improve intravaginal pressures, though there are no randomised controlled trials (class I studies) validating its use in this setting. Class I studies demonstrate a role for BoNT in the management of idiopathic detrusor overactivity, though long-term follow-up data are lacking. Potential problems with BoNT injection include toxin reactions, urinary and faecal incontinence, urinary retention and secondary treatment failure due to antibody production. CONCLUSIONS: A single class I study supports the use of BoNT for refractory pelvic floor spasm; however, further adequately powered class I studies for this indication and for provoked vestibulodynia are warranted.

My notes (saved in your browser only)

Condition tags

chronic_pelvic_paindyspareunia

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (87)

Source provenance

crossref
last seen: 2026-08-14T06:25:23.267117+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-08-22T06:23:50.750314+00:00
License: CC0 · commercial use OK